Affigen

Canada
Sydney Forks, Nova Scotia, Canada, V6Z 1Z7

Company profile

Affigen company profile

Affigen develops tumor-identifying therapies to treat cancer. By utilizing precision design, we can drive powerful immune responses against molecules unique to cancer, while minimizing the risk of damage to healthy tissues. To do this, we focus on highly-automated process engineering and personal-scale biologics manufacturing in order to develop new therapies for previously “undruggable” targets. In effect, we focus on cancer’s “Achille’s Heel”: the proteins which distinguish tumor cells from normal cells, which can target tumor cells for destruction with extreme sensitivity and precision. As a translational-stage company, we develop our therapeutics with rapid clinical adoption in mind, and in close collaboration with an extensive expert network of world-class academic collaborators.

Business identity

Contact email
[email protected]
Phone number
+113142545081
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2016-01-01, Year

Headquarters

Postal code
V6Z 1Z7
Country code
CA
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$17M
Last funding
Series A / $17M / 2017-02-21
Last equity funding
Series A / $17M
Investors
1
Lead investors
1
Founders
4
Articles
1

Founders and investors

Founders

Carlos F. SantosDavid J. StatesForrest CoxJonathan Feldmann

Lead investors

Black Beret Life Sciences

Investors

Black Beret Life Sciences